Singapore markets close in 2 hours 56 minutes

Kronos Bio, Inc. (KRON)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.7300+0.1500 (+4.19%)
At close: 04:00PM EDT
3.7300 0.00 (0.00%)
After hours: 04:02PM EDT

Kronos Bio, Inc.

1300 South El Camino Real
Suite 300
San Mateo, CA 94402
United States
650 781 5200
https://kronosbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees101

Key executives

NameTitlePayExercisedYear born
Dr. Norbert W. Bischofberger Ph.D.Pres, CEO & Director644.98kN/A1956
Mr. Joshua A. KazamCo-Founder & Director35kN/A1977
Dr. Yasir B. Al-Wakeel BCh, BM, MACFO & Head of Corp. Devel.789.29kN/A1982
Ms. Barbara A. Kosacz J.D.COO, Sec. & Gen. Counsel607.99kN/A1958
Dr. Christopher Dinsmore Ph.D.Chief Scientific Officer595.6k788.42k1967
Dr. Jorge F. DiMartino M.D., Ph.D.Chief Medical Officer & Exec. VP of Clinical Devel.640.21kN/A1964
Stephanie YaoExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Marni KottleSr. VP of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Charles Lin Ph.D.Sr. VP of BiologyN/AN/AN/A
Dr. Elizabeth A. Olek D.O., M.P.H.Sr. VP of Clinical Devel.N/AN/A1965
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Corporate governance

Kronos Bio, Inc.’s ISS governance QualityScore as of 1 September 2022 is 9. The pillar scores are Audit: 7; Board: 10; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.